BR112015018270A2 - composições que compreendem 15-ohepa e métodos de uso das mesmas - Google Patents

composições que compreendem 15-ohepa e métodos de uso das mesmas

Info

Publication number
BR112015018270A2
BR112015018270A2 BR112015018270A BR112015018270A BR112015018270A2 BR 112015018270 A2 BR112015018270 A2 BR 112015018270A2 BR 112015018270 A BR112015018270 A BR 112015018270A BR 112015018270 A BR112015018270 A BR 112015018270A BR 112015018270 A2 BR112015018270 A2 BR 112015018270A2
Authority
BR
Brazil
Prior art keywords
ohepa
compositions
methods
fatty liver
alcoholic
Prior art date
Application number
BR112015018270A
Other languages
English (en)
Portuguese (pt)
Inventor
Climax John
Rowe Jonathan
Duffy Kevin
Original Assignee
Dignity Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dignity Sciences Ltd filed Critical Dignity Sciences Ltd
Publication of BR112015018270A2 publication Critical patent/BR112015018270A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
BR112015018270A 2013-01-30 2014-01-24 composições que compreendem 15-ohepa e métodos de uso das mesmas BR112015018270A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1301626.6A GB201301626D0 (en) 2013-01-30 2013-01-30 Composition comprising 15-OHEPA and methods of using the same
PCT/EP2014/051455 WO2014118097A1 (en) 2013-01-30 2014-01-24 Compositions comprising 15-ohepa and methods of using the same

Publications (1)

Publication Number Publication Date
BR112015018270A2 true BR112015018270A2 (pt) 2017-07-18

Family

ID=47891001

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015018270A BR112015018270A2 (pt) 2013-01-30 2014-01-24 composições que compreendem 15-ohepa e métodos de uso das mesmas

Country Status (27)

Country Link
US (6) US20150224076A1 (https=)
EP (2) EP2762143B1 (https=)
JP (2) JP6363104B2 (https=)
KR (6) KR20230047201A (https=)
CN (2) CN111214464A (https=)
AU (2) AU2014211628B2 (https=)
BR (1) BR112015018270A2 (https=)
CA (1) CA2897343C (https=)
CY (1) CY1117209T1 (https=)
DK (1) DK2762143T3 (https=)
ES (2) ES2564025T3 (https=)
GB (1) GB201301626D0 (https=)
HR (1) HRP20160203T1 (https=)
HU (1) HUE026901T2 (https=)
IL (3) IL239893A (https=)
MX (2) MX364646B (https=)
NZ (1) NZ709803A (https=)
PH (1) PH12015501582B1 (https=)
PL (1) PL2762143T3 (https=)
PT (1) PT2762143E (https=)
RS (1) RS54584B1 (https=)
RU (2) RU2018136872A (https=)
SG (2) SG11201505457PA (https=)
SI (1) SI2762143T1 (https=)
SM (1) SMT201600069B (https=)
WO (1) WO2014118097A1 (https=)
ZA (2) ZA201505018B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
JP2016538288A (ja) 2013-11-15 2016-12-08 ディグニティ サイエンシス リミテッド 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩
EP3091959A4 (en) * 2014-01-10 2017-09-20 Dignity Sciences Limited Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
US20180008567A1 (en) * 2015-01-16 2018-01-11 Afimmune Limited Compositions comprising 15-hepe and methods of using the same
ES2980790T3 (es) 2015-04-28 2024-10-03 Basf As Acidos grasos estructuralmente mejorados que contienen azufre para su uso en el tratamiento de la esteatohepatitis no alcohólica
MA47141A (fr) * 2015-05-13 2019-11-06 Ds Biopharma Ltd Compositions comprenant du15-oxo-epa ou du 15-oxo-dgla et leurs procédés de préparation et d'utilisation
ES2851525T3 (es) * 2015-07-21 2021-09-07 Afimmune Ltd Composiciones que comprenden 15(S)-HEPE para su uso en la sensibilización de las células cancerosas a la radioterapia
CA3129008A1 (en) * 2015-12-18 2017-06-22 Afimmune Limited Compositions comprising 15-hepe and methods of using the same
IL308604B2 (en) 2017-12-06 2025-08-01 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
CN115215725A (zh) * 2021-04-15 2022-10-21 宋晓瑜 一种制备乙酸薰衣草酯及薰衣草醇的方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05186342A (ja) * 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
AU683027B2 (en) 1993-01-27 1997-10-30 Scotia Holdings Plc Triglycerides
JPH09505562A (ja) 1993-10-01 1997-06-03 アール．ピー．シェーラー コーポレイション 香料を小分けして提供する方法および組成物
US20020055539A1 (en) * 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
WO1999058120A1 (en) * 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
EP1762557B1 (en) 2000-02-16 2011-04-06 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
ATE291910T1 (de) 2001-05-30 2005-04-15 Laxdale Ltd Verwendung von coenzym q (ubiquinone) und eikosapentaensäure (epa) für die behandlung von non-hodgkin's lymphoma und psychiatrischen oder neurologischen erkrankungen
CN1250230C (zh) * 2001-09-30 2006-04-12 中国药品生物制品检定所 海狗油作为制备治脂肪肝药的应用
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
EP1711173A2 (en) 2003-12-31 2006-10-18 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or ester thereof
WO2005102309A2 (en) 2004-04-26 2005-11-03 Ltb4 Sweden Ab In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration
US20050282781A1 (en) 2004-06-18 2005-12-22 Shibnath Ghosal Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids
AU2005262392A1 (en) 2004-07-01 2006-01-19 Johnson & Johnson Vision Care, Inc. Compositions and methods for treating eye disorders and conditions
WO2007081773A2 (en) * 2006-01-05 2007-07-19 Reliant Pharmaceuticals, Inc Treatment of fatty liver
EP3285072B1 (en) 2006-08-08 2020-04-15 Metabolon, Inc. Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof
WO2008126363A1 (ja) * 2007-03-30 2008-10-23 Kowa Company, Ltd. 脂肪肝又は非アルコール性脂肪性肝炎の予防及び／又は治療のための医薬
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
US20110105510A1 (en) * 2008-06-17 2011-05-05 Hiroshi Ishikawa Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
WO2010095706A1 (ja) * 2009-02-20 2010-08-26 国立大学法人東京大学 新規抗炎症性化合物
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
CA2690488C (en) 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
JP5909183B2 (ja) * 2010-08-19 2016-04-26 国立大学法人 東京大学 オメガ３系脂肪酸由来の新規抗炎症性代謝物
WO2012031125A2 (en) 2010-09-01 2012-03-08 The General Hospital Corporation Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine
US10154977B2 (en) 2011-03-25 2018-12-18 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
RU2014119948A (ru) 2011-10-19 2015-11-27 Дигнити Сайенсиз Лимитед ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ DGLA И/ИЛИ 15-HETrE, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP2015500639A (ja) 2011-11-29 2015-01-08 ディグニティ サイエンシス リミテッド ２０−炭素脂肪酸を含む組成物ならびにその製造方法および使用方法
RS57777B1 (sr) 2012-01-06 2018-12-31 Omthera Pharmaceuticals Inc Dpa-obogaćene kompozicije omega-3 polinezasićenih masnih kiselina u obliku slobodne kiseline
US20120264705A1 (en) * 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
DK2858496T3 (da) * 2012-05-10 2023-07-24 Solutex Na Llc Olier med anti-inflammatorisk aktivitet, som indeholder naturlige specialiserede pro-afhjælpningsmediatorer og deres forløbere
GB201213484D0 (en) * 2012-07-30 2012-09-12 Dignity Sciences Ltd Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
ES2851525T3 (es) * 2015-07-21 2021-09-07 Afimmune Ltd Composiciones que comprenden 15(S)-HEPE para su uso en la sensibilización de las células cancerosas a la radioterapia
CA3129008A1 (en) 2015-12-18 2017-06-22 Afimmune Limited Compositions comprising 15-hepe and methods of using the same

Also Published As

Publication number Publication date
HUE026901T2 (en) 2016-07-28
ZA201505018B (en) 2017-01-25
KR20150112995A (ko) 2015-10-07
JP6363104B2 (ja) 2018-07-25
CN105120872A (zh) 2015-12-02
KR20250105691A (ko) 2025-07-08
HRP20160203T1 (hr) 2016-03-25
SI2762143T1 (sl) 2016-04-29
PL2762143T3 (pl) 2016-06-30
JP2018172409A (ja) 2018-11-08
CN111214464A (zh) 2020-06-02
US20250186384A1 (en) 2025-06-12
EP2762143A1 (en) 2014-08-06
CA2897343C (en) 2021-03-16
IL239893A (en) 2017-04-30
MX364646B (es) 2019-05-03
AU2018206685A1 (en) 2018-08-02
RU2015136849A (ru) 2017-03-06
DK2762143T3 (en) 2016-03-07
KR102434817B1 (ko) 2022-08-19
IL265876A (en) 2019-06-30
PT2762143E (pt) 2016-03-28
SMT201600069B (it) 2016-04-29
IL239893A0 (en) 2015-08-31
MX2019005082A (es) 2019-08-12
US20150224076A1 (en) 2015-08-13
SG11201505457PA (en) 2015-08-28
KR102514913B1 (ko) 2023-03-27
CY1117209T1 (el) 2017-04-05
JP2016511753A (ja) 2016-04-21
IL251639A0 (en) 2017-06-29
GB201301626D0 (en) 2013-03-13
EP3058943B1 (en) 2019-09-25
US20220347147A1 (en) 2022-11-03
MX2015009803A (es) 2015-10-29
KR20230047201A (ko) 2023-04-06
NZ709803A (en) 2020-05-29
CN105120872B (zh) 2020-01-10
ES2759448T3 (es) 2020-05-11
AU2014211628B2 (en) 2018-04-19
PH12015501582A1 (en) 2015-10-05
HK1200351A1 (en) 2015-08-07
RS54584B1 (sr) 2016-08-31
EP2762143B1 (en) 2015-12-02
KR20210088733A (ko) 2021-07-14
AU2014211628A1 (en) 2015-07-30
WO2014118097A1 (en) 2014-08-07
PH12015501582B1 (en) 2019-10-25
RU2018136872A (ru) 2018-11-27
SG10201806854XA (en) 2018-09-27
KR20220119524A (ko) 2022-08-29
ES2564025T3 (es) 2016-03-17
EP3058943A1 (en) 2016-08-24
RU2671208C2 (ru) 2018-10-30
US20210244697A1 (en) 2021-08-12
ZA201605125B (en) 2018-06-27
KR20240011872A (ko) 2024-01-26
US20210228524A1 (en) 2021-07-29
US20200069626A1 (en) 2020-03-05
KR102274963B1 (ko) 2021-07-08
US10813903B2 (en) 2020-10-27
CA2897343A1 (en) 2014-08-07

Similar Documents

Publication Publication Date Title
BR112015018270A2 (pt) composições que compreendem 15-ohepa e métodos de uso das mesmas
CO2018005361A2 (es) Formulaciones inyectables de toxina botulínica y sus métodos de uso que poseen efecto terapéutico o cosmético de larga duración
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
MX2017001279A (es) Usos y composiciones de la flagelina.
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
MX387604B (es) Formulaciones cannabinoides estables.
MX2016008448A (es) Conjugados de var2csa-farmaco.
WO2014197871A3 (en) Antibody-drug conjugates, compositions and methods of use
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
BR112016008576A2 (pt) Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
EA201692002A1 (ru) Стабильные составы для антител к cd19 и конъюгатов антитело-лекарственное средство
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
MX376122B (es) Composiciones de plinabulina.
BR112019005329A2 (pt) composições de oligossacarídeos de leite humano purificadas
MX2015012833A (es) Composiciones antibioticas de ceftolozano.
BR112015023387A2 (pt) composições lipídicas de racecodotril
BR112015004515A2 (pt) composição imunogênica
EA201690323A1 (ru) Способы лечения заболеваний уха у детей
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
PL423259A1 (pl) Koniugaty przeciwciało-ureaza dla celów terapeutycznych
UY35848A (es) Tienopirimidinas
DOP2016000007A (es) Pirazolpiridinas sustituidas
MX2013013393A (es) Composiciones de cuidado oral.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: AFIMMUNE LIMITED (IE)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]